HOBOKEN, N.J.--(BUSINESS WIRE)--Octapharma USA has awarded an educational grant to the Global Blood Disorder Foundation (GBDF) to sponsor the first national conference for patients with Type 3 von Willebrand Disease (VWD).
VWD affects up to 1 percent of the U.S. population. Type 3 VWD is the rarest and most severe form of the condition.
Resources and educational content will be available on wide-ranging medical topics, including diagnosis, symptoms, treatment options, and joint health. Psychosocial topics will tackle a wide range of issues such as family and professional relationships, emotional challenges of loss and depression, disclosure issues and positive coping strategies.
GBDF Board Member Edward Kuebler, a Senior Social Worker at the University of Texas Gulf States Hemophilia and Thrombophilia Treatment Center in Houston, noted that the conference has been in development for more than a year. “The end result of the extensive planning process is that we will bring together patients and their companions with a world class group of physicians and medical professionals in a safe and relaxed environment for making lifetime connections,” he said.
“It is a privilege for Octapharma USA to help Type 3 VWD patients connect with other patients and bleeding disorders community resources and information,” said Octapharma USA President Flemming Nielsen. “We are committed to programs and products that enable bleeding disorders patients to manage their condition and maximize quality of life. Patient needs should always come first.”
Throughout the conference, attendees will have access to a myriad of resources, including healthcare providers specializing in bleeding disorders, physicians, nurses, physical therapists, social workers, geneticists and health educators. For complete conference information, please visit www.GlobalBloodDF.org.
About the Global Blood Disorder Foundation
Global Blood Disorder Foundation is a Houston-based non-profit organization created to serve the bleeding disorders community worldwide through educational conferences, workshops and skill building training programs. For more information, please visit www.GlobalBloodDF.org.
About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs approximately 6,000 people worldwide to support the treatment of patients in over 100 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company’s American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com.